A combination of metoclopramide and selective serotonin reuptake inhibitors: additional extrapyramidal effects?

Introduction

Metoclopramide (Primperan®) is a prokinetic agent, which increases gastrointestinal motility. It was approved in the Netherlands in 1968. Metoclopramide possesses central and peripheral dopamine antagonistic properties and it acts on the peripheral 5HT₄-receptors, which results in acetylcholine release from the myenteric plexus [1]. The serotonin reuptake inhibitors (SSRIs) are widely used as antidepressants. SSRIs inhibit the presynaptic reuptake of serotonin. Some of the SSRIs have some acetylcholine antagonistic properties [1].

Extrapyramidal reactions occur during metoclopramide therapy due to the dopamine antagonism of metoclopramide. Extrapyramidal reactions have also been reported during the use of SSRIs. These reactions are probably caused by a serotonergic inhibition of the dopamine neurotransmission in the striatum [2,3]. The SPCs of metoclopramide and most of the SSRIs [4-11] do mention extrapyramidal symptoms as adverse drug reaction. However an additive effect or an interaction between metoclopramide and SSRIs is not mentioned in the SPC of either metoclopramide or the SSRIs [4-10].

Reports

Lareb received 6 reports of extrapyramidal symptoms during combined use of metoclopramide and SSRIs (table 1). All cases were reported by a health professional. In cases A and B the reporting health professional recognized the interaction between the SSRI and metoclopramide, in cases C, D and E the SSRI was mentioned as concomitant medication and in case F metoclopramide was considered as concomitant medication. The symptoms started within a few hours after metoclopramide was administered in cases A, B, C, D and E. In case B and case E the patient was admitted to the hospital because of the extrapyramidal reaction.

Table 1. reports of extrapyramidal reactions with metoclopramide and a SSRIs

<table>
<thead>
<tr>
<th>Patient, Sex, age</th>
<th>Existing therapy/ time to onset</th>
<th>Additional therapy/ time to onset</th>
<th>Adverse drug reaction</th>
<th>Action taken, outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>A, F, 32</td>
<td>fluvoxamine 50mg*/ 3 days</td>
<td>metoclopramide 10mg*/ hours</td>
<td>akathisia</td>
<td>both drugs withdrawn, recovered</td>
</tr>
<tr>
<td>B, F, 35</td>
<td>fluvoxamine 50mg*/ days</td>
<td>metoclopramide 10mg*/ hours</td>
<td>tardive dyskinesia, trismus</td>
<td>hospitalisation, both drugs withdrawn, recovered</td>
</tr>
<tr>
<td>C, F, 38</td>
<td>fluoxetine 20mg/ concomitant</td>
<td>metoclopramide 10mg*/ 1 day</td>
<td>dyskinesia</td>
<td>?, recovered</td>
</tr>
<tr>
<td>D, F, 44</td>
<td>paroxetine 20mg/ concomitant</td>
<td>metoclopramide 20mg*/ 6 hours</td>
<td>akathisia, dystonia</td>
<td>?, ?</td>
</tr>
<tr>
<td>E, F, 38</td>
<td>paroxetine 20mg/ concomitant</td>
<td>metoclopramide 20mg*/6 hours</td>
<td>extrapyramidal reaction</td>
<td>metoclopramide withdrawn, biperidene, recovered</td>
</tr>
<tr>
<td>F, F, 49</td>
<td>metoclopramide 10mg/ concomitant</td>
<td>sertraline 50mg*/ 3 days</td>
<td>dystonia, tinnitus</td>
<td>sertraline withdrawn, recovered</td>
</tr>
</tbody>
</table>

*suspected medication according to health professional
Other sources of information

Literature
In the Dutch interaction-reference-works the interaction between metoclopramide and SSRIs is not mentioned [13,14]. According to Stockley the additive effect of fluoxetine, fluvoxamine and sertraline and metoclopramide was reported in a few isolated case reports [15]. Fisher and Davis published two cases of a serotonin syndrome with serious extrapyramidal movement disorders. The symptoms appeared in two patients on chronic treatment with sertraline or venlafaxine after a single dose metoclopramide [16].

Mechanism
An explanation for these extrapyramidal symptoms is a pharmacodynamic interaction. SSRIs increase the serotonin activity, which inhibits the dopaminergic system, leading to severe extrapyramidal symptoms in combination with the antidopaminergic activity of metoclopramide.
In addition, a pharmacokinetic interaction should be taken into account. Metoclopramide is a known substrate for cytochrome P450 2D6. Citalopram, fluoxetine, paroxetine and sertraline are (weak) inhibitors of this enzyme [1,12]. A decreased metabolism of metoclopramide could enhance the interaction between metoclopramide and SSRI's.

Conclusion
Lareb received 6 reports of a possible interaction of metoclopramide and a SSRI shortly after start of the metoclopramide and some publications suggest that such interaction may occur. SSRIs and metoclopramide both have the potential to cause extrapyramidal reactions by itself. It is conceivable that the combination increases the risk for extrapyramidal symptoms.

References
1. KNMP; 2004 Informatorium medicamentorum 2004
2. Caley CF. Extrapyramidal reactions and selective serotonin-reuptake inhibitors. The annals of pharmacotherapy 1997;31:1481-7
12. Flockhart http://medicine.iupui.edu/flockhart/Januari 2004
14. Winap interacties via Kombirom januari 2004